Clinical trial
Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS
NCT00465296 · Medstar Health Research Institute, Other · Terminated
Key facts
| NCT number | NCT00465296 |
|---|---|
| Title | Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS |
| Official title | Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS |
| Lead sponsor | Medstar Health Research Institute, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 200 |
| Start date | Jan 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Apr 25, 2007 |
| Last update posted | May 22, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: